RxDoctor Payments DataLook up a doctor →

Dirk Davidson, MD

Medical Oncology · Crossville, TNNPI 1659369429

Payments from drug & device makers

$21,277in general payments, 2019–2025

Across 1,126 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Merck$1K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$20,28695%
  • Education$9915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)83$1,720
Novartis80$1,483
E.r. Squibb & Sons, L.L.C.89$1,398
Merck63$1,235
Johnson & Johnson48$1,162
Pfizer74$1,126
Genentech USA, Inc.56$820
Incyte Corporation41$797
Daiichi Sankyo Inc.32$672
Seagen Inc.34$649
Bristol Myers Squibb31$598
Takeda Pharmaceuticals U.S.A., Inc.29$567
Bayer32$566
Astellas Pharma US Inc23$517
Amgen33$517
Gilead(2 entities)29$516
Pharmacyclics LLC, An Abbvie Company22$453
Lilly USA, LLC25$450
AVEO Pharmaceuticals, Inc.8$360
Regeneron Healthcare Solutions, Inc.12$348
AbbVie16$333
GSK17$301
Array Biopharma Inc17$280
Eisai Inc.14$277
Sanofi13$271
EMD Serono, Inc.18$260
Exelixis Inc.13$241
Deciphera Pharmaceuticals Inc.9$219
Pharmacosmos Therapeutics Inc.11$192
Mirati Therapeutics, Inc.7$185
Ipsen Biopharmaceuticals, Inc10$177
Beigene USA, Inc.7$150
Coherus Oncology, Inc.6$132
Morphosys, US Inc.5$132
EUSA Pharma (US) LLC7$130
Rigel Pharmaceuticals, Inc.6$121
Puma Biotechnology, Inc.7$120
Sobi, Inc7$111
Pharmaessentia USA Corporation5$103
Tersera Therapeutics LLC6$100
Karyopharm Therapeutics Inc.3$98
Boehringer Ingelheim5$97
Adaptive Biotechnologies Corporation5$91
Dova Pharmaceuticals6$89
Genmab U.S., Inc.4$75
Jazz Pharmaceuticals Inc.5$75
Caris MPI, Inc.3$70
Sun Pharmaceutical Industries Inc.4$70
Acceleron Pharma, Inc.4$70
Taiho Oncology, Inc.3$57
Beone Medicines USA, Inc.3$57
Verity Pharmaceuticals Inc.3$48
Secura Bio, Inc.3$41
Otsuka America Pharmaceutical, Inc.2$41
Helsinn Therapeutics (U.S.), Inc.2$37
Sandoz2$37
Azurity Pharmaceuticals, Inc.2$35
Stemline Therapeutics Inc.1$33
Teva Pharmaceuticals USA, Inc.2$30
Avyxa Pharma, LLC1$27

How this compares

$21,277 in reported general payments places this provider in the 55th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,341,709
Medicare patients
959
Services billed
249,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide133$1,866,144
Lupron DepotLeuprolide Acetate171$994,322
Neulasta OnproPegfilgrastim75$621,995
ImbruvicaIbrutinib38$607,939
Darzalex FasproDaratumumab-Hyaluronidase-Fihj38$554,306
IbrancePalbociclib33$523,673
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5077$514,225
Lenalidomide45$484,883
KeytrudaPembrolizumab33$468,790
RevlimidLenalidomide32$452,561
InlytaAxitinib24$412,578
LenvimaLenvatinib Mesylate17$401,969
TagrissoOsimertinib Mesylate23$376,532
TecentriqAtezolizumab36$371,642
CalquenceAcalabrutinib Maleate25$309,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$517$1,866,144133 claims
PfizerIbrance, Inlyta, Zirabev, Ruxience, Retacrit$1,126$1,209,571112 claims
AbbVieLupron Depot, Venclexta$333$1,140,055183 claims
E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst, Reblozyl$1,398$713,57755 claims
NovartisSandostatin Lar Depot, Mekinist, Tafinlar, Promacta$1,483$710,64486 claims
AstraZenecaTagrisso, Calquence$1,720$686,50348 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Entyvio$567$632,16891 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$453$607,93938 claims
AmgenProlia, Xgeva$517$507,508238 claims
MerckKeytruda$1,235$468,79033 claims
Bristol Myers SquibbRevlimid$598$452,56132 claims
Eisai Inc.Lenvima$277$401,96917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 101 medical oncology providers in Tennessee.

Other medical oncology in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →